Table 1. Relationship between clinicopathological features and IL-22 or IL-22R1 expression in patients with gastric cancer.
| Number of IL-22 positive/total number of patients | P-value | Number of IL-22R1 positive/total number of patients | P-value | |
|---|---|---|---|---|
| Tumour location |
|
0.8975 |
|
0.4784 |
| Lower | 7/9 (77.8%) | 9/9 (100%) | ||
| Mid | 11/13 (84.6%) | 12/13 (92.3%) | ||
| Upper |
11/14 (78.6%) |
|
12/14 (85.7%) |
|
| Lauren's classification |
|
0.5515 |
|
> 0.9999 |
| Intestinal type | 9/12 (75.0%) | 11/12 (91.7%) | ||
| Diffuse type |
20/24 (83.3%) |
|
22/24 (91.7%) |
|
| Stage |
|
0.0035 |
|
0.3729 |
| I | 3/8 (37.5%) | 7/8 (87.5%) | ||
| II | 5/5 (100%) | 5/5 (100%) | ||
| III | 12/12 (100%) | 12/12 (100%) | ||
| IV |
9/11 (81.1%) |
|
9/11 (81.1%) |
|
| Lymphatic invasion |
|
0.0031 |
|
0.0282 |
| None | 0/2 (0.0%) | 1/2 (50.0%) | ||
| Present |
29/34 (85.3%) |
|
32/34 (94.1%) |
|
| Venous invasion |
|
0.3464 |
|
0.4185 |
| None | 4/6 (66.7%) | 5/6 (83.3%) | ||
| Present |
25/30 (83.3%) |
|
28/30 (93.3%) |
|
| Lymph node metastasis |
|
0.0016 |
|
0.7277 |
| None | 4/9 (44.4%) | 8/9 (88.9%) | ||
| Present | 25/27 (92.6%) | 25/27 (92.6%) |
Abbreviations: IL-22=interleukin-22; IL-22R1=IL-22 receptor 1. P-values <0.05 are indicated by bold entries.